Salute e Benessere

Virbac : Declaration of the number of shares and voting rights 04/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsApril, 30 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
07/05/2025

Zentiva Joins the Call to Action to Finalize Pharmaceutical Reform and Secure…

This is not just another technical EU policy. It is about ensuring that every European, wherever they live, can access the medicines they need. It's about avoiding shortages, bringing production back toEurope, and making our health systems more resilient and fair. It is also about making the industry robust for the future, recognising investments in sustainability like reducing carbon emissions and increasing the use of renewable energy at our manufacturing sites. Zentiva is...
PR Newswire
07/05/2025

Companion Diagnostics Market Set to Surpass USD 12 Billion by 2031 with a CAGR…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27J1624/Global_Companion_Diagnostic_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-27J1624/Global_Companion_Diagnostic_Market Major Factors Driving the Growth of Companion Diagnostics Market: The companion diagnostics market is a vital segment of precision healthcare, offering tailored treatment strategies based on individual patient profiles. It plays a crucial role...
PR Newswire
07/05/2025

Corticosteroid API Market Poised for a 6% CAGR Growth Through 2031: What You…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-21K14628/Global_Corticosteroid_API_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-21K14628/Global_Corticosteroid_API_Market Major Factors Driving the Growth of Corticosteroid API Market: The corticosteroid API market forms a critical backbone for the production of anti-inflammatory and immunosuppressive drugs used globally across a range of therapeutic areas...
PR Newswire
07/05/2025

Updated full-year outlook for 2025 as a result of DTK closing, market conditions…

Company announcement no. 07 – 25 7 May 2025 Updated full-year outlook for 2025 as a result of DTK closing, market conditions and M&A integration projectsNTG has completed the acquisition of DTKOn 7 May 2025, we completed the acquisition of DTK. Despite the current headwinds in market, this strategic milestone is expected to have a positive impact on our full year performance and is expected to contribute with approximately DKK 75 million to our adjusted EBIT in 2025. The...
Nasdaq GlobeNewswire
07/05/2025

In Vitro Diagnostics Market Size to be Worth $150.13 Billion by 2030 at CAGR…

Request a free sample copy or view report summary: In Vitro Diagnostics Market Request a free sample copy or view report summary:In Vitro Diagnostics Market In Vitro Diagnostics Market Report Highlights: Read full market research report on In Vitro Diagnostics (IVD) Market with TOC - In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By End Use (Hospitals, Laboratory), By Application, By Technology...
PR Newswire
07/05/2025

MRI Systems Market worth US$9.01 billion by 2030 with 6.5% CAGR |…

Browse in-depth TOC on "MRI Systems Market" Browse in-depth TOC on "MRI Systems Market" 300 - Tables 50 - Figures 180 - Pages By Based on field strength,The global MRI systems market is categorized based on field strength into three segments: low-to-mid-field, high & very-high-field, and ultra-high-field MRI systems. The ultra-high-field sector is projected to experience the highest CAGR during the forecast period. Ultra-high-field MRI systems offer a superior...
PR Newswire
07/05/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 7 May 2025 at 17.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 6 May 2025 above...
Nasdaq GlobeNewswire
07/05/2025

Vistin Pharma ASA (VISTN): Update from the Election Committee

The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA.The Election Committee has therefore assessed the consequences of this for the recommendation submitted 13 March 2025 to this year's annual general meeting. Øystein Spetalen was the only board member up for election, and it was recommended that he was re-elected. The composition of the board's expertise has been assessed, and it has been...
Nasdaq GlobeNewswire
07/05/2025

SkinShop.ie Takes Ireland by Storm as the Ultimate Destination for Korean Beauty…

Among the first to introduce Korean skincare to the Irish market, SkinShop.ie recognised the potential of K-Beauty long before it became a viral phenomenon. Having built an extensive offering over the past two years, the brand now boasts the largest selection of Korean skincare in Ireland — stocking some of the most sought-after names in the industry, including Medicube, Skin1004, Anua, Beauty of Joseon, Biodance, HaruHaru Wonder and Dr. Althea — with more exciting brand launches on the horizon.
PR Newswire
07/05/2025

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

The closing of the Offering is expected to occur on or about May 8, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this Offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. The Company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although it currently has no commitments or...
Nasdaq GlobeNewswire
07/05/2025

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and…

th -10 thMay 2025.In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO) mouse model, ETX‑312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP‑1/GIP receptor agonist or an FGF‑21 analogue. All mice receiving combination therapy achieved ≥ 2‑point reductions in NAS, with improvements of up to 5 points observed.Slowed fibrosis progression comparable to that achieved with GLP‑1/GIP receptor agonist or...
Nasdaq GlobeNewswire
07/05/2025

Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical…

Key Clinical Results and Future Plans Key Clinical Results and Future Plans Differentiation Through Innovative Recombinant Collagenase Currently, Endo's Xiaflex is the only commercially available collagenase injection for Dupuytren's contracture. CNT201 is being developed as an alternative to Xiaflex and is expected to significantly improve patient access to non-surgical treatment. Collagenase is originally produced by fermentation of the pathogenic microorganismClostridium...
PR Newswire
07/05/2025

Pioneering the future of sports with iPS cells FUNROOTS, I Peace, and Reju form…

Induced pluripotent stem (iPS) cells, renowned for their ability to regenerate and repair human tissue, offer transformative potential for sports medicine. The partnership aims to apply this technology to accelerate the healing of common sports injuries such as joint, muscle, and ligament damage while developing preventive care methods that help athletes maintain optimal health throughout and beyond their professional careers. Induced pluripotent stem (iPS) cells, renowned for their ability…
PR Newswire
07/05/2025

Lunit to Power Germany's Largest Private Radiology Network with AI Imaging

Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH healthcare market, Starvision is known for its commitment to digital transformation, operational excellence, and high-quality patient care. Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH...
PR Newswire
07/05/2025

Minaris Advanced Therapies launches as the leading global partner dedicated to…

With modern facilities approved for commercial production in the United States (Allendale, NJ and Philadelphia), Europe (Munich) and Asia-Pacific (Yokohama, Japan), Minaris Advanced Therapies manufactures clinical-stage and commercial products on three continents and has a proven track record of delivering more than 7,500 GMP batches. With modern facilities approved for commercial production inthe United States( Allendale, NJandPhiladelphia ),Europe( Munich ) andAsia-Pacific(...
PR Newswire
07/05/2025

THE WORLD'S MOST FAMOUS AND PAMPERED FELINE CHOUPETTE STARS IN HUBLOT'S BIG BANG…

The campaign unveils Hublot's new tagline – "Own It". A bold and unapologetic call to action, and an uncompromising mindset. This new mantra captures the authentic, loud, and polarising spirit of the brand. Hublot has chosen the one and only Choupette, who doesn't have a wrist or know how to tell the time. Choupette, a cultural icon, brings her signature attitude to a campaign that celebrates outrageous confidence and radical individuality that define both her and Hublot. The campaign…
PR Newswire
07/05/2025

Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial…

ENDOFIRST-QUARTER FINANCIAL PERFORMANCE(in thousands) ENDOFIRST-QUARTER FINANCIAL PERFORMANCE (in thousands) CONSOLIDATED RESULTS Total revenues in first-quarter 2025 were$393 million, a decrease of 6% compared to$420 millionin first-quarter 2024. This change was primarily attributable to competitive pressure across the Sterile Injectables and Generic Pharmaceuticals segments, partially offset by Branded Pharmaceuticals revenue growth. Net Loss in first-quarter 2025 was...
PR Newswire
07/05/2025

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation.Due to limited capacity, in-person attendance is by invitation only. Analysts and institutional investors will be invited to pre-register and attend through an invite that will is distributed separately.For questions regarding the event, please contact Teva's Investor Relations team at ...
Nasdaq GlobeNewswire
07/05/2025

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative…

For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO ®– shows continued strong growth, with worldwide revenues of $411...
Nasdaq GlobeNewswire
07/05/2025

Safe Life Acquires AEDMAX.PL, Enters Polish Market

"Welcoming AEDMAX.PL into Safe Life is an honor and a privilege, and marks an important step on our expansion journey," says Jimmy Eriksson, CEO of Safe Life. "Their success to date builds on strengths in market position, team and product & service portfolio, and I see fantastic opportunities ahead when marrying those to the platform and depth of expertise we have across Safe Life. Poland is a very large and bustling market, and we are extremely pleased to have AEDMAX.PL join…
PR Newswire
07/05/2025

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved…

- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC -- VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint -- Greater differences between the treatment arms were observed in patients receiving 2 doses of...
Nasdaq GlobeNewswire
07/05/2025

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on…

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which...
Nasdaq GlobeNewswire
07/05/2025

Oculis to Present at Upcoming May Investor Conferences

/ ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, Belgium Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America Healthcare ConferenceMay 13-15, 2025; Las Vegas, USA...
Nasdaq GlobeNewswire
07/05/2025
Altri  Comunicati